Caribou Biosciences, Inc.
CRBUNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $1.7M |
| Operating income | −$148.3M | −$166.6M | −$116.1M | −$106.4M | −$67.0M | −$10.4M |
| Net income | −$148.1M | −$149.1M | −$102.1M | −$99.4M | −$66.9M | −$9.8M |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M | $36.0M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M | $18.2M |
| Equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M | −$23.4M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | — |
| Shares out. | 93.0M | 90.3M | 61.3M | 60.7M | 60.3M | 9.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1329.4%
- Net margin
- −1327.4%
- Return on equity
- −121.2%
- Return on assets
- −84.5%
- Return on capital (ROCE)
- −98.9%
- Liabilities / assets
- 30.3%
- Debt / equity
- 0.44×
- Book value / share
- $1.31
- Revenue growth (YoY)
- 11.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.88distress
- Accruals / assets
- −21.2%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Vanguard Group IncPassive (13G)Apr 30, 2025
- Haurwitz Rachel E.Activist (13D)Apr 25, 2025
- Bank Of America Corp /De/Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.1M | 4.5 | +0.2% |
| Apr 30, 2026 | 7.1M | 4.3 | +5.3% |
| Apr 15, 2026 | 6.8M | 5.5 | +4.6% |
| Mar 31, 2026 | 6.5M | 6.0 | -8.3% |
| Mar 13, 2026 | 7.1M | 6.2 | -2.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Regulation FD disclosure · Other material eventMar 31, 2026
- Results of operationsMar 5, 2026
- Results of operationsNov 12, 2025
- Results of operations · Regulation FD disclosure · Other material eventNov 3, 2025
- Results of operationsAug 12, 2025
- Other material eventJun 23, 2025
- Shareholder voteJun 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.